Cancer Care Stakeholders’ Organization Names Former FDA Commissioner Keynote Speaker

Press Releases — July 26, 2019

Scott Gottlieb, MD, to Take the Podium at Annual AVBCC Summit

CRANBURY, New Jersey, July 26, 2019—The Association for Value-Based Cancer Care (AVBCC) is delighted to announce that Scott Gottlieb, MD, former US Food and Drug Administration Commissioner, will be the keynote speaker at the 2019 AVBCC Summit on Thursday, October 17, in New York City. The AVBCC Summit is the premier gathering of practitioners, pharmacists, payers, policymakers, and other stakeholders from across the cancer-care spectrum. The 3-day professional conference is held annually and will be returning to the historic New York Athletic Club in Manhattan, October 16-18.

As 23rd Commissioner of the FDA, Dr Gottlieb gained international recognition during his tenure for his aggressive advocacy in improving patients’ healthcare access and for record numbers of approvals of innovative drugs and medical devices and affordable generic drugs. While he was at its head, the agency made groundbreaking advancements in gene therapies, targeted drugs, and digital health devices. Among his many accomplishments in office, he put in place policies to reduce death and disease from tobacco, improve food safety, and confront the addiction crises.

Dr Gottlieb is recognized as a leading thinker in the evolving healthcare and business nexus. In both 2018 and 2019 Fortune honored him as one of the “World’s 50 Greatest Leaders.” In its annual survey of 50 physician executives, Modern Healthcare named him one of the “Most Influential Physician Executives and Leaders” and in 2018 Time named Dr Gottlieb one of “50 People Transforming Healthcare.”

He is a member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC. He has been published in top medical journals and has held editorial positions on The British Medical Journal and The Journal of the American Medical Association. He has written for general interest periodicals, including The Wall Street Journal, The New York Times, and The Washington Post, and appears regularly as a commentator on the cable television network CNBC.

Dr Gottlieb is returning to the private sector following an unparalleled term of leadership as one of the architects of today’s healthcare landscape, and in his keynote address, “Opinions and Thoughts on the Future of Cancer Care in America,” he will share insights he has gained through his long career at the forefront of change with the AVBCC Summit attendees.

“We are thrilled that Scott will be speaking at the Summit. He is a true visionary,” said AVBCC Founder and Co-Chair Burt Zweigenhaft. Now in its 9th year, the AVBCC Summit brings together nationally recognized experts, faculty speakers, panelists, key opinion leaders, C-suite executives, and managers whose goals are to improve patient care and maximize patient access and outcomes through care coordination. “With our emphasis on sharing best practices and developing quality measures in the value-based cancer care arena, I can think of no one better to kick off this year’s meeting.”

Dr Gottlieb’s address will be one of the highlights among the many anticipated during the 3 full days of planned workshops, panel discussions, sponsored knowledge exchanges, and impromptu conversations. Other scheduled speakers will be announced in the coming weeks. More information about the full agenda, presenters, and registration is available on the 2019 AVBCC Summit overview page.

AVBCC was established nearly a decade ago to provide a network for payers and oncology healthcare professionals to interact and exchange knowledge to promote optimal care for patients and their families. It currently consists of more than 450 members and is the fastest growing national specialty organization dedicated to improving the care of cancer patients and their quality of life, by discussing, considering, and assessing the value equation as it relates to new and existing cancer therapies.

The true partner of global healthcare companies, Amplity Health continually challenges the boundaries of medical and commercial strategies to accelerate the approval and launch of new drugs to improve the lives of patients. We are proud of our inclusive culture and our EPIIC values. Amplity has the expertise, global infrastructure, and data-driven insights to help clients overcome their medical and commercial challenges.

Amplity’s wide-ranging capabilities include clinical and medical outsourced teams; clinical and medical capability development; companion diagnostic and precision medicine solutions; medical communications; expert engagement; remote and field solutions for patients, payers, and physicians; and strategic and access consulting. Amplity’s one-of-a-kind Insights database offers clients a detailed view into patient–provider interactions and provider treatment rationale not found through any other provider.

For more information, visit amplity.com. Connect with Amplity on Twitter and LinkedIn.

Amplity Health is a portfolio company of Altamont Capital Partners.

Related Articles